RxDoctor Payments Data

Erin Allen, DO

Family Medicine · Yukon, OKNPI 1548360779

Payments from drug & device makers

$10,114in general payments, 2019–2025

Across 666 payments — averaging $15.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • Pfizer$1K
  • Novo Nordisk$979
  • AstraZeneca$950
  • AbbVie$854
  • GSK$541
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$10,01199%
  • Education$1031%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,114 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$92,625
Medicare patients
266
Services billed
1,507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide96$125,059
JardianceEmpagliflozin68$89,693
OzempicSemaglutide61$75,620
TrulicityDulaglutide27$46,824
EliquisApixaban37$44,220
FarxigaDapagliflozin Propanediol26$31,687
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$31,037
RybelsusSemaglutide13$28,204
JanuviaSitagliptin Phosphate23$17,247
MyrbetriqMirabegron19$15,629
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$9,457
Tresiba Flextouch U-100Insulin Degludec15$9,201
Atorvastatin Calcium374$4,544
Levothyroxine Sodium408$3,690
Montelukast Sodium171$3,678

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,228$171,882123 claims
Novo NordiskOzempic, Rybelsus$979$103,82474 claims
Boehringer IngelheimJardiance$248$89,69368 claims
PfizerEliquis, Premarin$1,107$47,22351 claims
GSKTrelegy Ellipta, Anoro Ellipta$541$40,49452 claims
AstraZenecaFarxiga$950$31,68726 claims
MerckJanuvia$355$17,24723 claims
Astellas Pharma US IncMyrbetriq$476$15,62919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Yukon

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →